Welcome to the Novo Nordisk Inc. ISS Management system for investigator-sponsored studies. This site allows you to submit an application to Novo Nordisk for ISS support and is restricted to the submission of ISS grant requests only. If you would like to submit a grant request for an independent medical education program, please visit https://www.novonordisk.com/external-support

The review of an ISS begins with submission of a concept. The decision is then made to invite a full protocol or decline. Please allow a minimum of 8 months to review both the concept and full protocol. Submission of an application does not mean that Novo Nordisk has agreed to provide support for your study. Decisions are made only after Novo Nordisk has made a comprehensive review of your complete application. All requests are reviewed for scientific merit, compliance with legal, ethical, and professional obligation, as well as fiscal responsibility.

For additional information regarding the ISS submission process, click here for a Quick Reference Guide.

*Please note that all new ISS applications for Semaglutide (e.g., injectables and oral formulation) are currently on pause and thus, not being accepted.The pause will remain through 2023 and will be re-evaluated in Q1 2024.

Should you have questions regarding the pause on ISS submissions related to semaglutide, or the Novo Nordisk ISS program/review process, please feel free to reach out to your local Medical Liaison or email Dr. Jamie Coborn, the ISS Director at NNI_ISS@novonordisk.com.

If you need technical assistance, please call + 1 718-576-1406 or click here to contact the Steeprock system administrator.